Stephanie Wingerter
Primary Care · Indiana, PANPI 1518473602
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,505 of the $6,697 with a category attached, or 67.3%. 22 manufacturers reported payments, led by Axonics, Inc. at 25.5% of the total. Reporting peaked in 2022 at $2,461 and has fallen 82.4% since, to $432 in 2025. Among primary care clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $26.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Astellas Pharma US Inc$1K
- Teleflex LLC$1K
- Sumitomo Pharma America, Inc.$654
- Pfizer$516
- Johnson & Johnson$395
- plus $1K from 16 others
What the payments were for
- Travel & lodging$1,69225%
- Food & beverage$4,50567%
- Education$5007%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 43 | $1,710 |
| Astellas Pharma US Inc | 50 | $1,183 |
| Teleflex LLC | 19 | $1,119 |
| Sumitomo Pharma America, Inc. | 38 | $654 |
| Pfizer | 26 | $516 |
| Johnson & Johnson | 19 | $395 |
| Urovant Sciences Inc | 13 | $219 |
| Medtronic | 7 | $151 |
| Cumberland Pharmaceuticals, Inc. | 6 | $104 |
| Ferring Pharmaceuticals Inc. | 6 | $103 |
| AbbVie | 4 | $97 |
| 180 Medical, Inc. | 3 | $79 |
| Verity Pharmaceuticals Inc. | 4 | $76 |
| Boston Scientific | 3 | $57 |
| Myovant Sciences Inc. | 3 | $56 |
| Antares Pharma, Inc. | 2 | $41 |
| Halozyme Inc | 2 | $40 |
| Tolmar Pharmaceuticals, Inc. | 2 | $31 |
| Convatec Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Olympus America Inc. | 1 | $17 |
| Dentsply IH Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bulkamid$1,038
- Axonics$1,038
- UroLift System$773
How this compares
$6,697 in reported general payments places this provider in the 95th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 301 | $231,427 |
| Mirabegron ErMirabegron | 80 | $51,475 |
| GemtesaVibegron | 24 | $22,111 |
| Tamsulosin Hcl | 924 | $21,963 |
| Finasteride | 373 | $6,892 |
| Solifenacin Succinate | 142 | $5,861 |
| NitrofurantoinNitrofurantoin Macrocrystal | 111 | $3,999 |
| Tadalafil | 13 | $3,895 |
| Fosfomycin Tromethamine | 19 | $2,287 |
| Testosterone | 24 | $2,115 |
| Oxybutynin Chloride ErOxybutynin Chloride | 82 | $1,950 |
| Ciprofloxacin Hcl | 113 | $1,310 |
| Trimethoprim | 12 | $1,157 |
| Bethanechol Chloride | 14 | $1,055 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 28 | $906 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,183 | $231,427301 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $654 | $22,11124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 300 primary care providers in Pennsylvania.
Other primary care in Indiana
- Ashley PrugerIndiana$7K
- Kersten ReiderMount Penn$121K
- Teresa GiamboyPhiladelphia$21K
- Nicole IlgenfritzBethel Park$18K
- Galyna VorokhibPhiladelphia$12K
- Melissa BeansWarrington$12K
- Mollie McGuireJohnstown$11K
- Andrea MauriceNew Cumberland$11K
- Kendell SoglieroSmithfield$9K
- Minjung RegerDoylestown$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.